ArticleImmunotherapy advances2022

Target isoforms are an overlooked challenge and opportunity in chimeric antigen receptor cell therapy.

Mike Bogetofte Barnkob et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.